ImmuPharma (LON:IMM) Shares Up 27.3% - What's Next?

Key Points

• ImmuPharma plc shares surged 27.3% on Saturday, closing at GBX 12.60 ($0.17), after trading as high as GBX 12.75 ($0.17).
• The company reported a net margin of 3,519.56% for the quarter but has a negative return on equity of 131.41%.
• ImmuPharma focuses on developing peptide-based therapeutics for autoimmune diseases, with its lead program Lupuzor™ targeting Lupus and related conditions.

ImmuPharma plc (LON:IMM - Get Free Report) traded up 27.3% on Saturday . The company traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). 4,543,810 shares were traded during mid-day trading, a decline of 46% from the average session volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Stock Up 27.3%

The stock has a market capitalization of £63.34 million, a price-to-earnings ratio of -1,415.73 and a beta of 1.53. The company has a 50 day moving average of GBX 7.92 and a 200 day moving average of GBX 4.36.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.